RAPT Therapeutics, Inc., was incorporated in March 2015 under the laws of the State of Delaware. The Company is a clinical-stage, immunology-based biopharmaceutical company dedicated to the discovery, development and commercialization of oral small molecule therapies for patients who are not fully satisfied in oncology and inflammatory diseases. Using its proprietary drug discovery and development engine, the company develops highly selective small molecules designed to modulate key immune responses in these diseases. 

Expected P&L on Expiry

Key Stats

Pricing Model

About RAPT20260220C40